Literature DB >> 17543784

Post-conditioning protects from cardioplegia and cold ischemia via inhibition of mitochondrial permeability transition pore.

René Ferrera1, Jean-Chrisostome Bopassa, Denis Angoulvant, Michel Ovize.   

Abstract

BACKGROUND: The aim of this study was to evaluate the role of the mitochondrial permeability transition pore (MPTP) in the protection achieved by post-conditioning of hearts submitted to hypothermic cardioplegia and ischemia.
METHODS: Isolated rat hearts (n = 30) underwent cold cardioplegia (4 degrees C, Celsior solution) and 8 hours of ischemia at 4 degrees C, followed by a 60-minute Langendorff reperfusion. Hearts were randomly assigned to one of two groups: post-conditioning (post-C, consisting of episodes of 30-second ischemia and 30-second reperfusion at onset of reperfusion) or control (no intervention). A sham group was added for which hearts were harvested and immediately reperfused without ischemia. Coronary flow, heart rate, dP/dt and rate-pressure product were measured. Infarct size was assessed by triphenyltetrazolium chloride (TTC) staining and lactate dehydrogenase (LDH), creatine phosphokinase (CPK) and troponin I release analysis. After reperfusion, heart mitochondria were isolated and calcium overload necessary to induce MPTP opening was measured. From the onset of reperfusion, all functional parameters were significantly improved in post-C vs control hearts.
RESULTS: Infarct size, measured both by TTC staining and LDH, and CPK and troponin I leakage were lower in post-C hearts (p < 0.01). Mean calcium load needed to induce MPTP opening was higher in post-C mitochondria vs controls (p < 0.01).
CONCLUSIONS: Post-conditioning protects the rat heart against cold ischemia-reperfusion injury. Our data suggest that this protection involves inhibition of MPTP opening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17543784     DOI: 10.1016/j.healun.2007.02.009

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

1.  Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling.

Authors:  Jiahui Yu; Lingyan Wang; Mary Akinyi; Yuhong Li; Zhenzhen Duan; Yan Zhu; Guanwei Fan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Critical role of mitochondrial ROS is dependent on their site of production on the electron transport chain in ischemic heart.

Authors:  Ngonidzashe B Madungwe; Netanel F Zilberstein; Yansheng Feng; Jean C Bopassa
Journal:  Am J Cardiovasc Dis       Date:  2016-09-15

3.  Inner mitochondrial membrane protein MPV17 mutant mice display increased myocardial injury after ischemia/reperfusion.

Authors:  Ngonidzashe B Madungwe; Yansheng Feng; Abdulhafiz Imam Aliagan; Nathalie Tombo; Ferdinand Kaya; Jean C Bopassa
Journal:  Am J Transl Res       Date:  2020-07-15       Impact factor: 4.060

Review 4.  Sterile inflammation in thoracic transplantation.

Authors:  C Corbin Frye; Amit I Bery; Daniel Kreisel; Hrishikesh S Kulkarni
Journal:  Cell Mol Life Sci       Date:  2020-08-17       Impact factor: 9.261

5.  Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling.

Authors:  Guanwei Fan; Jiahui Yu; Patrick Fordjour Asare; Lingyan Wang; Han Zhang; Boli Zhang; Yan Zhu; Xiumei Gao
Journal:  J Cell Mol Med       Date:  2016-07-07       Impact factor: 5.310

6.  Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels.

Authors:  Yansheng Feng; Ngonidzashe B Madungwe; Abdulhafiz D Imam Aliagan; Nathalie Tombo; Jean C Bopassa
Journal:  Biochem Biophys Res Commun       Date:  2019-10-14       Impact factor: 3.575

7.  An inhibitor of the δPKC interaction with the d subunit of F1Fo ATP synthase reduces cardiac troponin I release from ischemic rat hearts: utility of a novel ammonium sulfate precipitation technique.

Authors:  Mourad Ogbi; Ijeoma Obi; John A Johnson
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.